1. Home
  2. JANX vs CNXC Comparison

JANX vs CNXC Comparison

Compare JANX & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$16.52

Market Cap

975.7M

Sector

Health Care

ML Signal

HOLD

Logo Concentrix Corporation

CNXC

Concentrix Corporation

HOLD

Current Price

$25.71

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
JANX
CNXC
Founded
2017
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
975.7M
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
JANX
CNXC
Price
$16.52
$25.71
Analyst Decision
Strong Buy
Buy
Analyst Count
18
4
Target Price
★ $36.24
$33.50
AVG Volume (30 Days)
784.9K
★ 1.7M
Earning Date
11-05-2026
09-29-2026
Dividend Yield
N/A
★ 5.94%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 1.20
Revenue
$10,000,000.00
★ $9,825,771,000.00
Revenue This Year
$194.24
$0.32
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$22.51
Revenue Growth
N/A
★ 2.15
52 Week Low
$12.12
$19.12
52 Week High
$35.34
$49.37

Technical Indicators

Market Signals
Indicator
JANX
CNXC
Relative Strength Index (RSI) 44.93 43.44
Support Level $15.75 $25.33
Resistance Level $16.68 $26.39
Average True Range (ATR) 0.69 1.99
MACD -0.06 -0.48
Stochastic Oscillator 44.67 24.01

Price Performance

Historical Comparison
JANX
CNXC

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About CNXC Concentrix Corporation

Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.

Share on Social Networks: